The Trump Administration is committed to lowering drug prices for all Americans. It is pursuing this goal through a multifaceted approach led by the Department of Health and Human Services. The Administration also realizes that it must take into account the need for protection of intellectual property for pharmaceuticals and other American innovative industries. In trade negotiations we generally try to encourage other countries to adopt U.S. standards.
It is important to note that nothing in the newly negotiated USMCA will require changing U.S. laws on pharmaceutical intellectual property rights or lead to higher prices on drugs for U.S. consumers. We look forward to working with Congress on these and other issues in our trade agreement.